Navigation Links
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
Date:2/24/2009

PRINCETON, N.J., Feb. 24 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced the appointment of Dr. Marcel Rozencweig as Senior Executive Vice President for Clinical Affairs. Prior to joining Sopherion, Dr. Rozencweig was a key Clinical Development Consultant to the Company and a member of the Sopherion Protocol Development Team for Myocet.

"I am excited to continue to contribute to the development of Myocet," said Dr. Rozencweig. "Myocet has the potential to be a valued addition to the first-line treatment regimen for metastatic breast cancer, particularly in patients with HER-2 overexpression."

Dr. Rozencweig was previously with GPC-Biotech since 2001. He has 18 years of experience with Bristol-Myers Squibb, where he held several senior leadership positions in drug development and strategic planning, including Vice President, Oncology, Infectious Diseases and Immunology Clinical Research; and Vice President, Strategic Planning and Portfolio Management.

"Dr. Rozencweig's world-renowned experience in oncology drug development is an ideal fit for Sopherion as we move Myocet forward," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "His many achievements include significant contributions leading to the FDA approval of 11 drugs, mostly anticancer treatments, including the blockbusters Taxol(R) and Paraplatin(R) (carboplatin)."

Dr. Rozencweig is an Adjunct Associate Professor of Medicine at New York University and has authored or co-authored more than 200 scientific publications.

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering with advanced cancer, particularly metastatic disease. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion entered into an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc. for the future commercialization of Myocet in North America. For more information, visit www.sopherion.com.


'/>"/>
SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics to Resume Trading on MTA and NASDAQ
2. United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results
3. Cell Therapeutics Updates Shareholders on Trading
4. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
5. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
6. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
7. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
8. Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference
9. Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
11. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... In the ... forward. They’ll groom themselves to perfection, go out of their way to be romantic, ... – just take a look at any online dating profile. , A recent ...
(Date:2/12/2016)... , ... February 12, 2016 , ... According to an ... are beginning to account for a significant portion of hernia repairs throughout the United ... the Beverly Hills Hernia Center notes that this trend has not only been expected, ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & ... purpose of these scholarships is to encourage applicants to pursue a degree in their ... these two parishes. , “We have available jobs in St. Landry and Evangeline ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February ...
(Date:2/12/2016)... ... 12, 2016 , ... Fixed Dose Combination Drug Development: , ... http://www.fdanews.com/fixeddosecombination , Fixed dose combination products are a ... from all stakeholders in the development of new chemical entities. , However, the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... N.J. , Feb. 12, 2016  Innophos Holdings, Inc. ... and nutritional specialty ingredients, today announced that it will host ... 10:00 am ET to discuss its fourth quarter and full ... --> The press release detailing fourth quarter and full ... after market close. --> ...
(Date:2/12/2016)... Inc., a medical device company that pioneered the use of the ... device indicated for fusion for certain disorders of the sacroiliac (SI) ... Contractor (MAC) covering the states of Connecticut , ... Massachusetts , Minnesota , ... Rhode Island , Vermont and ...
(Date:2/12/2016)... 12, 2016 On Thursday, Feb. 11, 2016, ... St. David,s North Austin Medical Center successfully completed the ... Xi ® Surgical System with Trumpf Medical,s advanced ... Thiru Lakshman , M.D., colorectal surgeon at the Texas ... Integrated Table Motion technology, which seamlessly combines the da ...
Breaking Medicine Technology: